BANK VONTOBEL/CALL/NOVO NORDISK ADR B/160/0.1/16.08.24 | Market Closed - Börse Stuttgart 02:19:06 2024-06-28 EDT | ||
| 0.24 EUR | +2.13% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.24 | +2.13% |
| 24-06-27 | 0.235 | -18.97% |
| 24-06-26 | 0.29 | +31.82% |
| 24-06-25 | 0.22 | +19.57% |
| 24-06-24 | 0.184 | +7.60% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 02:19 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD7QV2 |
| ISIN | DE000VD7QV29 |
| Date issued | 2024-06-10 |
| Strike | 160 $ |
| Maturity | 2024-08-16 (47 Days) |
| Parity | 10 : 1 |
| Emission price | 0.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.29 € |
|---|---|
| Lowest since issue | 0.17 € |
| Spread | 0.01 € |
| Spread % | 4.83% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
